EGFR and posterior cortical atrophy: While a few trials showed moderate results in a subpopulation of PCa patients (e.g. erlotinib had moderate single-agent activity in chemotherapy-naïve CRPC, while cetuximab had some activity in those overexpressing EGFR and showing consistent expression of the tumor suppressor PTEN) [18, 19], the majority of these trials failed to demonstrate efficacy.